The vaccine is expected to cost Rs 2,145 per patient and is expected to be launched in the private market across 11 states, including Gujarat.
Dr Manjul Joshipura, senior vice president of Innovations and New Products at Cadila Pharma, said the vaccine has been in development since 2010.
After introducing it in the private sector, the company may consider approaching the government as well as adding it to the rabies vaccine basket at government facilities, but must negotiate the price with the government. government, he added.
Results of the vaccine’s phase 3 clinical trial involving 800 volunteers between the ages of 18 and 65 were published in September 2021 in Vaccines and immunotherapy for humans Journal.
Based on available studies and literature, approximately 30-40 percent of patients quit after three doses of an existing five-dose regimen due to complex dosing schedules, frequent visits to the hospital or clinic, and the ability to loss of income related to these visits , said Dr. Ravish HS of the Department of Community Medicine . So, he said, the three-dose regimen of ThRabis should solve this problem.
Since rabies is not a dangerous disease, there is a lack of India-wide data on the incidence of animal bites and rabies, Founding Chairman of the Association for Rabies Prevention and Control in India (APCRI), Dr. MK Sudarshan told The Indian Express.
According to surveys conducted by APCRI, the total number of animal bites recorded in 7 states including Himachal Pradesh, Bihar, West Bengal, Manipur, Kerala, Madhya Pradesh, Gujarat has increased from 998,276 in 2012 to 1.17. 873 in 2016.
The term ThRabis vaccine is “overate“, Dr. Sudarshan suggested that the company conduct a”after-market surveillance“to explore the success of vaccines in the pediatric population and to conduct studies with special populations such as pregnant women and immunosuppressed individuals.